CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex
Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing
of its public offering of 9,100,000 shares of its common stock at a price
of $33.00 per share. The gross proceeds, before commissions and expenses,
of the public offering will be approximately $300.3 million. All of the
shares are being offered by Vertex. The Company has also granted the
underwriters a 30-day option to purchase up to an additional 900,000 shares
to cover over-allotments, if any.
Merrill Lynch, Pierce, Fenner & Smith Incorporated is acting as sole
book-runner, with Morgan Stanley & Co. Incorporated acting as joint lead
manager and UBS Securities LLC acting as co-manager in this offering.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws
of any such state. A shelf registration statement relating to the shares of
common stock that the Company intends to sell has been filed with the
Securities and Exchange Commission. Any offer of shares of common stock
will be made only by means of a prospectus, including a prospectus
supplement, forming a part of this effective registration statement. A copy
of the final prospectus can be obtained from Merrill Lynch's prospectus
department, at 4 World Financial Center, New York, NY 10080, 212-449-1000.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is focused on viral diseases,
inflammation, autoimmune diseases, cancer, pain and bacterial infection.
Vertex co-discovered the HIV protease inhibitor, Lexiva, with
GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com
Vertex Contacts:
Lynne H. Brum, VP, Strategic Communications, (617) 444-6614
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com/
http://www.prnewswire.com/comp/938395.html /
CONTACT:
Lynne H. Brum, VP, Strategic Communications,
+1-617-444-6614, or Michael Partridge, Director, Corporate
Communications, +1-617-444-6108, or Lora Pike, Manager, Investor
Relations, +1-617-444-6755, all of Vertex Pharmaceuticals
Incorporated
|
